Pathogen Infection as a Possible Cause for Autoimmune Hepatitis

REFERENCES

• Manns MP, Czaja AJ, Gorham JD, Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51(6):2193–2213.
   PubMed Web of Science ®Google Scholar
• Vierling JM. Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep 2012;14(1):25–36.
   PubMedGoogle Scholar
• Lohse AW, Wiegard C. Diagnostic criteria for autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25(6):665–671.
   PubMedGoogle Scholar
• Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010;139(1):58–72.
   PubMedGoogle Scholar
• Boberg KM, Chapman RW, Hirschfield GM, Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54(2):374–385.
   PubMed Web of Science ®Google Scholar
• Organization WH. Environmental health criteria 236: principles and methods for assessing autoimmunity associated with exposure to chemicals. http://wwwwhoint/ipcs/publications/ ehc/ehc236pdf. 2006.
   Google Scholar
• Nelson SD, Pearson PG. Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Annu Rev Pharmacol Toxicol 1990;30:169–195.
   PubMed Web of Science ®Google Scholar
• Park BK, Kitteringham NR. Drug-protein conjugation and its immunological consequences. Drug Metab Rev 1990;22(1):87–144.
   PubMedGoogle Scholar
• Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993;58(2):133–155.
   PubMed Web of Science ®Google Scholar
• Christen U. Pathogen infection and autoimmunity. Int Rev Immunol 2014;33(4):261–265.
   PubMed Web of Science ®Google Scholar
• Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol 1999;163(6):3202–3210.
   PubMedGoogle Scholar
• Reinhardt RL, Khoruts A, Merica R, Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001;410(6824):101–105.
   PubMed Web of Science ®Google Scholar
• Limmer A, Ohl J, Kurts C, Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000;6(12):1348–1354.
   PubMed Web of Science ®Google Scholar
• Bowen DG, Zen M, Holz L, The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004;114(5):701–712.
   PubMed Web of Science ®Google Scholar
• Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003;3(1):51–62.
   PubMed Web of Science ®Google Scholar
• Chen CH, Kuo LM, Chang Y, In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 2006;44(5):1171–1181.
   PubMedGoogle Scholar
• Luth S, Huber S, Schramm C, Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest 2008;118(10):3403–3410.
   PubMedGoogle Scholar
• Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002;6(3):635–647.
   PubMedGoogle Scholar
• Czaja AJ. Autoimmune hepatitis—approach to diagnosis. Med Gen Med 2006;8(2):55.
   PubMedGoogle Scholar
• Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54–66.
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB, International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929–938.
   PubMed Web of Science ®Google Scholar
• Hennes EM, Zeniya M, Czaja AJ, Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169–176.
   PubMed Web of Science ®Google Scholar
• Christen U. The role of autoantibodies in autoimmune hepatitis type 2. Immunotherapy 2013;5(3):247–256.
   PubMedGoogle Scholar
• Liberal R, Mieli-Vergani G, Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmunity 2013;46:17–24.
   PubMedGoogle Scholar
• Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 1991;11(3):215–222.
   PubMedGoogle Scholar
• Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001;120(6):1502–1517.
   PubMedGoogle Scholar
• Strassburg CP, Manns MP. Therapy of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25(6):673–687.
   PubMedGoogle Scholar
• Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012;57(8):1996–2010.
   PubMedGoogle Scholar
• Zachou K, Gatselis N, Papadamou G, Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011;55(3):636–646.
   PubMedGoogle Scholar
• Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25(6):653–664.
   PubMedGoogle Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105(5):1502–1507.
   PubMedGoogle Scholar
• Czaja AJ, Strettell MD, Thomson LJ, Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25(2):317–323.
   PubMedGoogle Scholar
• Tracy S, Drescher KM, Chapman NM, Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. J Virol 2002;76(23):12097–111.
   PubMedGoogle Scholar
• Horwitz MS, Bradley LM, Harbertson J, Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998;4(7):781–785.
   PubMed Web of Science ®Google Scholar
• Schubert C. News Feature: the worm has turned. Nat Med 2004;10(12):1271–1272.
   PubMedGoogle Scholar
• Zaccone P, Fehervari Z, Jones FM, Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur J Immunol 2003;33(5):1439–1449.
   PubMed Web of Science ®Google Scholar
• Christen U, Benke D, Wolfe T, Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest 2004;113(1):74–84.
   PubMedGoogle Scholar
• Zaccone P, Fehervari Z, Phillips JM, Parasitic worms and inflammatory diseases. Parasite Immunol 2006;28(10):515–523.
   PubMed Web of Science ®Google Scholar
• Christen U, von Herrath MG. Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference? Cell Mol Immunol 2011;8(3):193–8.
   PubMedGoogle Scholar
• Vento S, Garofano T, Di Perri G, Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991;337(8751):1183–1187.
   PubMedGoogle Scholar
• Vento S, McFarlane BM, McSorley CG, Liver autoreactivity in acute virus A, B and non-A, non-B hepatitis. J Clin Lab Immunol 1988;25(1):1–7.
   PubMedGoogle Scholar
• Gregorio GV, Pensati P, Iorio R, Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;112(3):471–476.
   PubMedGoogle Scholar
• Lenzi M, Bellentani S, Saccoccio G, Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999;45(3):435–441.
   PubMed Web of Science ®Google Scholar
• Badiani RG, Becker V, Perez RM, Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? World J Gastroenterol: WJG. 2010;16(29):3704–3708.
   PubMedGoogle Scholar
• Ferri S, Muratori L, Quarneti C, Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol 2009;50(6):1093–1101.
   PubMed Web of Science ®Google Scholar
• Dalekos GN, Wedemeyer H, Obermayer-Straub P, Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999;30(3):366–375.
   PubMedGoogle Scholar
• Muratori P, Muratori L, Verucchi G, Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis: an official publication of the Infectious Diseases Society of America. 2003;37(10):1320–1326.
   PubMedGoogle Scholar
• Bortolotti F, Muratori L, Jara P, Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr 2003;142(2):185–190.
   PubMedGoogle Scholar
• Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 2004;1(1):2.
   PubMedGoogle Scholar
• Strassburg CP, Vogel A, Manns MP. Autoimmunity and hepatitis C. Autoimmunity Rev 2003;2(6):322–331.
   PubMed Web of Science ®Google Scholar
• Ferri S, Muratori L, Lenzi M, HCV and autoimmunity. Curr Pharm Des 2008;14(17):1678– 1685.
   PubMedGoogle Scholar
• Caredda F, de Bartolo G, Zampini L, Detection and further characterization of a newly described microsomal autoantibody associated with chronic delta infection. Digestion 1986;33(4):181–188.
   PubMedGoogle Scholar
• Durazzo M, Philipp T, Van Pelt FN, Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology 1995;108(2):455–462.
   PubMedGoogle Scholar
• Csepregi A, Nemesanszky E, Luettig B, LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol 2001;96(3):910–911.
   PubMedGoogle Scholar
• Gregorio GV, Jones H, Choudhuri K, Autoantibody prevalence in chronic hepatitis B virus infection: effect in interferon alfa. Hepatology 1996;24(3):520–523.
   PubMedGoogle Scholar
• Vergani D, Mieli-Vergani G. Autoimmune manifestations in viral hepatitis. Semin Immunopathol 2013;35(1):73–85.
   PubMed Web of Science ®Google Scholar
• Vergani D, Alvarez F, Bianchi FB, Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41(4):677–683.
   PubMed Web of Science ®Google Scholar
• Marceau G, Lapierre P, Beland K, LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology 2005;42(3):675–682.
   PubMedGoogle Scholar
• Holdener M, Hintermann E, Bayer M, Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008;205(6):1409–22.
   PubMedGoogle Scholar
• Hintermann E, Holdener M, Bayer M, Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmunity 2011;37(3):242–253.
   PubMedGoogle Scholar
• Gueguen M, Boniface O, Bernard O, Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody. J Autoimmunity 1991;4(4):607–615.
   PubMedGoogle Scholar
• Kitazawa E, Igarashi T, Kawaguchi N, Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients. J Autoimmunity 2001;17(3):243–249.
   PubMedGoogle Scholar
• Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88(4):1370–1378.
   PubMed Web of Science ®Google Scholar
• Yamamoto AM, Cresteil D, Boniface O, Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993;23(5):1105–1111.
   PubMedGoogle Scholar
• Rigopoulou EI, Smyk DS, Matthews CE, Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol 2012;2012:987471.
   PubMedGoogle Scholar
• Zellos A, Spoulou V, Roma-Giannikou E, Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? Ann Hepatol 2013;12(1):147–151.
   PubMedGoogle Scholar
• Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008;22(5):883–896.
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1(1):75–82.
   PubMed Web of Science ®Google Scholar
• Vento S, Guella L, Mirandola F, Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995;346(8975):608–609.
   PubMedGoogle Scholar
• Koay LB, Tsai SL, Sun CS, Wu KT. Chronic autoimmune hepatitis with Epstein–Barr virus superinfection: a case report and review of literature. Hepato-Gastroenterol 2008;55(86–87):1781–1784.
   PubMedGoogle Scholar
• Aceti A, Mura MS, Babudieri S, Bacciu SA. A young woman with hepatitis after a sore throat. Lancet 1995;346(8990):1603.
   PubMedGoogle Scholar
• Nobili V, Comparcola D, Sartorelli MR, Autoimmune hepatitis type 1 after Epstein-Barr virus infection. Pediatr Infect Dis J 2003;22(4):387.
   PubMedGoogle Scholar
• Kojima K, Nagayama R, Hirama S, Epstein-Barr virus infection resembling autoimmune hepatitis with lactate dehydrogenase and alkaline phosphatase anomaly. J Gastroenterol 1999;34(6):706–712.
   PubMedGoogle Scholar
• Cabibi D. Autoimmune hepatitis following Epstein-Barr virus infection. BMJ Case Reports 2008;2008:bcr0620080071.
   PubMedGoogle Scholar
• Chiba T, Goto S, Yokosuka O, Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004;16(2):225–228.
   PubMedGoogle Scholar
• Nakajima S, Umebayashi H, Kurosawa R, [A case of autoimmune hepatitis needed to be differentiated from EBV hepatitis, in that the histology of liver biopsy specimen was useful for diagnosis]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology. 2005;28(3):154–158.
   PubMedGoogle Scholar
• Christie KE, Haukenes G. Measles virus-specific IgM antibodies in sera from patients with chronic active hepatitis. J Med Virol 1983;12(4):267–272.
   PubMedGoogle Scholar
• Robertson DA, Zhang SL, Guy EC, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987;2(8549):9–11.
   PubMedGoogle Scholar
• Mieli-Vergani G, Sutherland S, Mowat AP. Measles and autoimmune chronic active hepatitis. Lancet 1989;2(8664):688.
   PubMedGoogle Scholar
• Vento S, Cainelli F, Ferraro T, Concia E. Autoimmune hepatitis type 1 after measles. Am J Gastroenterol 1996;91(12):2618–2620.
   PubMedGoogle Scholar
• Al-Hamoudi WK. Severe autoimmune hepatitis triggered by varicella zoster infection. World J Gastroenterol: WJG 2009;15(8):1004–1006.
   PubMedGoogle Scholar
• Toyoda-Akui M, Yokomori H, Kaneko F, Association of an overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis with cytomegalovirus infection. Int J Gen Med 2011;4:397–402.
   PubMedGoogle Scholar
• Hagel S, Bruns T, Herrmann A, Autoimmune hepatitis in an HIV-infected patient: an intriguing association. Int J STD & AIDS. 2012;23(6):448–450.
   PubMedGoogle Scholar
• Tunccan OG, Tufan A, Telli G, Visceral leishmaniasis mimicking autoimmune hepatitis, primary biliary cirrhosis, and systemic lupus erythematosus overlap. Korean J Parasitol 2012;50(2):133–136.
   PubMed Web of Science ®Google Scholar
• Christen U, Hintermann E, Jaeckel E. New animal models for autoimmune hepatitis. Semin Liver Dis 2009;29(3):262–272.
   PubMedGoogle Scholar
• Meyer zum Buschenfelde KH, Kossling FK, Miescher PA. Experimental chronic active hepatitis in rabbits following immunization with human liver proteins. Clin Exp Immunol 1972;11(1):99–108.
   PubMedGoogle Scholar
• Kuriki J, Murakami H, Kakumu S, Experimental autoimmune hepatitis in mice after immunization with syngeneic liver proteins together with the polysaccharide of Klebsiella pneumoniae. Gastroenterology 1983;84(3):596–603.
   PubMedGoogle Scholar
• Lohse AW, Manns M, Dienes HP, Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990;11(1):24–30.
   PubMedGoogle Scholar
• Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992;90(1):196–203.
   PubMed Web of Science ®Google Scholar
• Gantner F, Leist M, Lohse AW, Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995;21(1):190–198.
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Van Kaer L, Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Nat Acad Sci USA 2000;97(10):5498–5503.
   PubMed Web of Science ®Google Scholar
• Dennert G, Aswad F. The role of NKT cells in animal models of autoimmune hepatitis. Crit Rev Immunol 2006;26(5):453–473.
   PubMedGoogle Scholar
• Moriyama T, Guilhot S, Klopchin K, Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990;248(4953):361–364.
   PubMed Web of Science ®Google Scholar
• Ando K, Guidotti LG, Wirth S, Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 1994;152(7):3245–3253.
   PubMedGoogle Scholar
• Limmer A, Sacher T, Alferink J, Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol 1998;28(8):2395–2406.
   PubMedGoogle Scholar
• Sacher T, Knolle P, Nichterlein T, CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur J Immunol 2002;32(12):3628–3637.
   PubMedGoogle Scholar
• Voehringer D, Blaser C, Grawitz AB, Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 2000;165(5):2415–2422.
   PubMedGoogle Scholar
• Oldstone MBA, Nerenberg M, Southern P, Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response. Cell 1991;65:319–331.
   PubMed Web of Science ®Google Scholar
• Ohashi P, Oehen S, Buerki K, Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305–317.
   PubMed Web of Science ®Google Scholar
• Christen U, Herrath MG. Initiation of autoimmunity. Curr Opin Immunol 2004;16(6):759–767.
   PubMedGoogle Scholar
• von Herrath MG, Dockter J, Oldstone MBA. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994;1:231–242.
   PubMed Web of Science ®Google Scholar
• Hintermann E, Ehser J, Christen U. The CYP2D6 animal model: how to induce autoimmune hepatitis in mice. J Visualized Experiments : JoVE. 2012;60(e3644):1–7.
   Google Scholar
• Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. A Nat 1964;98(900):129–149.
   Google Scholar
• Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the ‘glass of molecular mimicry’ half full or half empty? J Autoimmunity 2010;34(1):38–44.
   PubMedGoogle Scholar
• Hintermann E, Ehser J, Bayer M, Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6. J Autoimmunity 2013;44:49–60.
   PubMedGoogle Scholar
• Ehser J, Holdener M, Christen S, Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmunity 2013(42):39–49.
   PubMedGoogle Scholar
• Bogdanos DP, Lenzi M, Okamoto M, Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004;17(1):83–92.
   PubMedGoogle Scholar
• Hardtke-Wolenski M, Fischer K, Noyan F, Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology 2013;58(2):718–728.
   PubMedGoogle Scholar
• Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004;39(4):1066–1074.
   PubMedGoogle Scholar
• Aparicio JL, Pena C, Retegui LA. Autoimmune hepatitis-like disease in C57BL/6 mice infected with mouse hepatitis virus A59. Int Immunopharmacol 2011;11(10):1591–1598.
   PubMedGoogle Scholar
• Alexander J, del Guercio MF, Frame B, Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Vaccine 2004;22(19):2362–2367.
   PubMedGoogle Scholar
• von Herrath MG, Fujinami RS, Whitton JL. Microorganisms and autoimmunity: making the barren field fertile. Nat Rev Microbiol 2003;1:151–157.
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmunity Rev 2004;3(1):61–69.
   PubMedGoogle Scholar